---
schema_version: "secwatch.filing_event.v1"
accession: "0001055726-25-000064"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:11:59.588710+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INOVIO completes rolling BLA for INO-3107; Q3 net loss $45.5M, cash runway into Q2 2026

## Summary
- Completed rolling BLA submission for INO-3107 (RRP); priority review requested; potential FDA decision mid-2026.
- Net loss of $45.5M ($0.87/share) versus $25.2M loss a year ago; operating loss improved to $21.2M from $27.3M.
- Cash and short-term investments $50.8M as of Sept 30, 2025; estimated runway into Q2 2026 with Q4 cash burn ~$22M.
- R&D expenses fell to $13.3M from $18.7M; G&A expenses $7.9M down from $8.6M year-over-year.
- Phase 1 DMAb data for COVID-19 published in Nature Medicine; demonstrated durable antibody expression in humans.

## SEC filing metadata
- accession: 0001055726-25-000064
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000064/0001055726-25-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000105572625000064/ino-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001055726-25-000064
- JSON: https://secwatch.observer/filing/0001055726-25-000064.json
- Plain text: https://secwatch.observer/filing/0001055726-25-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.